Frontier Science Scotland has announced the appointment of Professor Bjoern Schelter as a new Director to its Board of Trustees.
Bjoern brings valuable strategic insights into the Company’s core capabilities across clinical trials including data management, biostatistical analysis and quality assurance.
Bjoern is CEO of GT Diagnostics (UK) Ltd and Chief Analytics Officer of TauRx Therapeutics, and is also affiliated with the University of Aberdeen as Professor for Applied Mathematics.
With over 20 years’ experience in the healthcare sector, Bjoern has led research teams since 2006. The focus of his work is on developing data-science based technologies to advance the understanding of diseases and ultimately help patients around the world.
Professor Chris Robertson, of the Department of Mathematics and Statistics at the University of Strathclyde, reflected: “I am delighted to welcome Bjoern to the FSS Board of Trustees.
“His extensive leadership experience in healthcare R&D, specifically in data-science based technologies and quality assurance in clinical trials, will be a source of invaluable advice as FSS expands its service offering to global industry partners.”
Bjoern added: “I am deeply interested in FSS and its outstanding services through a not-for-profit model. I look forward to assisting FSS to develop its services and grow as an organisation.”
